bisoprolol has been researched along with Renal Insufficiency in 3 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 7.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "The WB-PBPK model successfully predicts the intravenous and oral pharmacokinetics of bisoprolol across multiple dose levels in diverse normal adult human populations and patients with renal insufficiency." | 3.78 | Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. ( Chen, R; Li, GF; Wang, K; Yang, J; Zhao, HR; Zheng, QS, 2012) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 3.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castagno, D | 1 |
| Jhund, PS | 1 |
| McMurray, JJ | 1 |
| Lewsey, JD | 1 |
| Erdmann, E | 2 |
| Zannad, F | 1 |
| Remme, WJ | 1 |
| Lopez-Sendon, JL | 1 |
| Lechat, P | 2 |
| Follath, F | 1 |
| Höglund, C | 1 |
| Mareev, V | 1 |
| Sadowski, Z | 1 |
| Seabra-Gomes, RJ | 1 |
| Dargie, HJ | 1 |
| Li, GF | 1 |
| Wang, K | 1 |
| Chen, R | 1 |
| Zhao, HR | 1 |
| Yang, J | 1 |
| Zheng, QS | 1 |
| Verkenne, P | 1 |
| Wiemann, H | 1 |
1 trial available for bisoprolol and Renal Insufficiency
| Article | Year |
|---|---|
Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Double-Blind Method; Female; Heart Failure; Humans; M | 2010 |
2 other studies available for bisoprolol and Renal Insufficiency
| Article | Year |
|---|---|
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Topics: Administration, Intravenous; Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adult; Ar | 2012 |
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Bisoprolol; Cause of Death; | 2001 |